Palovarotene Capsule shortage
Palovarotene Capsule is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Oct 3, 2026.
Ipsen Biopharmaceuticals is stopping production of Sohonos (palovarotene) 2.5 mg capsules, and this change may be permanent. Other strengths of Sohonos (1 mg, 1.5 mg, 5 mg, and 10 mg capsules) are still listed as available from Ipsen Biopharmaceuticals.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Palovarotene Capsule. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Aug 31, 2026Currently in shortage1 of 1 product affected.
-
Aug 31, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Ipsen Biopharmaceuticals, Inc. 📞 (855)-463-5127 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | SOHONOS, Capsule, 2.5 mg (NDC 15054-0025-1) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Palovarotene Capsule — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Palovarotene Capsule? options further down this page.
Why is Palovarotene Capsule in shortage?
Ipsen Biopharmaceuticals has reported to the FDA that it is permanently stopping the manufacturing of Sohonos (palovarotene) 2.5 mg capsules. This means that specific product — the 2.5 mg strength — will no longer be made by this company going forward.
Ipsen did not share a more detailed public reason for why they are discontinuing production, so unfortunately I can't give you a clearer explanation beyond what they reported. It's also worth knowing that this report only reflects what Ipsen has filed with the FDA, so it speaks only to their product and their decision.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Palovarotene Capsule, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Palovarotene Capsule?
Palovarotene capsules (brand name Sohonos) are currently on the FDA shortage list, and I want to walk you through what this means.
The 2.5 mg strength is the one affected here, and it has no available source right now. The manufacturer, Ipsen Biopharmaceuticals, has reported this as a discontinuation — meaning they are stopping production of the 2.5 mg capsule. Because this is a discontinuation rather than a temporary delay, this supply problem may be permanent, so a conversation with your prescriber is the right next step.
I do want to note that the same medicine, Sohonos, is still listed in other strengths (1 mg, 1.5 mg, 5 mg, and 10 mg). This matters because your care team may be able to use a different strength to reach your prescribed dose.
Here is what I suggest:
- Do not stop, skip, or change your dose on your own.
- Ask your prescriber or pharmacist about options — for example, combining other available Sohonos strengths to make up your usual dose, or another clinician-chosen plan.
- Your pharmacy can check wholesalers and confirm what is currently in stock.
Manufacturer contact numbers are listed on this page for reference, though your pharmacy usually handles those calls.
This is general, national information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Palovarotene Capsule?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Palovarotene Capsule is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Sohonos | PALOVAROTENE 1 mg/1 | Capsule · Oral | Ipsen Biopharmaceuticals, Inc. | 15054-0010-01 |
| Sohonos | PALOVAROTENE 1.5 mg/1 | Capsule · Oral | Ipsen Biopharmaceuticals, Inc. | 15054-0015-01 |
| Sohonos | PALOVAROTENE 5 mg/1 | Capsule · Oral | Ipsen Biopharmaceuticals, Inc. | 15054-0050-01 |
| Sohonos | PALOVAROTENE 10 mg/1 | Capsule · Oral | Ipsen Biopharmaceuticals, Inc. | 15054-0100-01 |
Therapeutic equivalents & pricing 1 productclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Sohonos 2.5 mg | Ipsen | 14 capsules | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Identity & classification
Where does this data come from?
Palovarotene Capsule shortage FAQs
Is Palovarotene Capsule in shortage?
Which products are affected?
When will Palovarotene Capsule be available again?
Can I still get Palovarotene somewhere?
What should I do if I take Palovarotene Capsule?
Still have a question about the Palovarotene Capsule shortage?
Ask a pharmacist about this shortage →View Palovarotene Capsule on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.